Investment In Basic Research Research Articles

Human Capital, Basic Research, and Applied Research: Three Dimensions of Human Knowledge and Their Differential Growth Effects

We analyze the differential growth effects of basic research, applied research, and embodied human capital accumulation in an R&D-based growth model with endogenous fertility and endogenous education. In line with the empirical evidence, our model allows for i) a negative association between long-run economic growth and population growth, ii) a positive association between long-run economic growth and education, and iii) a positive association between the level of per capita GDP and expenditures for basic research. Our results also indicate that raising public investments in basic research reduces the growth rate of GDP in the short run because resources have to be drawn away from other productive sectors of the economy. These short-run costs of basic research might be an explanation for the reluctance of governments to increase public R&D expenditures notwithstanding the long-run benefits of such a policy.

The NIMH Research Domain Criteria (RDoC) Project: implications for genetics research

Heterogeneity of disorders, comorbidity across diagnoses, and reification of existing disease classifications are some of the challenges facing psychiatry in the twenty-first century. NIMH's Research Domain Criteria (RDoC) Project seeks to address these issues by defining basic dimensions of function that cut across disorders as traditionally defined and can be studied across multiple units of analysis, from genes to neural circuits to behaviors. The intent is to translate rapid progress in basic genetic, neurobiological, and behavioral research to an improved integrative understanding of psychopathology. In so doing, RDoC seeks to facilitate the development of new and/or optimally targeted treatments for mental disorders. The RDoC project would not have been possible without NIMH's long-term investment in basic research. Without the continuation of basic research, both related and unrelated to current RDoC domains and constructs, it will not be possible to sustain the RDoC effort. This article seeks to outline the relationship between RDoC and NIMH's ongoing support for broad-based basic research, from genetics to behavior.

Global nanotechnology development from 1991 to 2012: patents, scientific publications, and effect of NSF funding

In a relatively short interval for an emerging technology, nanotechnology has made a significant economic impact in numerous sectors including semiconductor manufacturing, catalysts, medicine, agriculture, and energy production. A part of the United States (US) government investment in basic research has been realized in the last two decades through the National Science Foundation (NSF), beginning with the nanoparticle research initiative in 1991 and continuing with support from the National Nanotechnology Initiative after fiscal year 2001. This paper has two main goals: (a) present a longitudinal analysis of the global nanotechnology development as reflected in the United States Patent and Trade Office (USPTO) patents and Web of Science (WoS) publications in nanoscale science and engineering (NSE) for the interval 1991–2012; and (b) identify the effect of basic research funded by NSF on both indicators. The interval has been separated into three parts for comparison purposes: 1991–2000, 2001–2010, and 2011–2012. The global trends of patents and scientific publications are presented. Bibliometric analysis, topic analysis, and citation network analysis methods are used to rank countries, institutions, technology subfields, and inventors contributing to nanotechnology development. We then, examined how these entities were affected by NSF funding and how they evolved over the past two decades. Results show that dedicated NSF funding used to support nanotechnology R&D was followed by an increased number of relevant patents and scientific publications, a greater diversity of technology topics, and a significant increase of citations. The NSF played important roles in the inventor community and served as a major contributor to numerous nanotechnology subfields.

On the Global Supply of Basic Research

In a two-country Schumpeterian growth model, we study the incentives for basic research investments by governments in a globalized world. We find that a country's basic research investments increase with the country's level of human capital and decline with its own market size. This may explain that some smaller countries invest a lot in basic research. Compared with the optimal investments achievable when countries coordinate their basic research policies, a single country may over-invest in basic research. However, the total amount of decentralized basic research investments is always below the socially optimal investment level, which justifies policy coordination in this area.

Nanomanufacturing: path to implementing nanotechnology

Research and development work in nanoscience and nanotechnology has generated new fundamental understanding of physical phenomena and material behaviour at the nano-scale. This knowledge has resulted in discoveries of new materials, structures and devices. It is believed that these basic research investments should now lead to new products and applications. The general feeling is that nanotechnology needs to move from fundamentals to practice, from the laboratory to the marketplace. The broad consensus is that we need accelerated research and development investments in nanomanufacturing science to step up transition of nanotechnology and to hasten technology transfer. Such an effort will fulfil nanotechnology’s promise, which to bring about economic and societal benefits. This paper will define and discuss our perspective on nanomanufacturing, describe our manufacturing science programmes ongoing research and development efforts, list manufacturing challenges and discuss how these are being met through our basic research programmes.

South Korea’s president-elect promises science boost

Park Geun-hye vows to raise investment in basic research and to accelerate Moon-lander plans.

Impact of Government Investments in Research & Innovation: A Review of Academic Investigations

In the interests of providing government policy makers and research managers with an appreciation of the scope, findings, and value of the academic literature, and of facilitating policy making that is informed by evidence, we conduct a systematic review of the recent academic literature on the impact of government investments in research and innovation. Our review considers 50 articles published in the leading academic journals between 2000 and 2012. We examine research on a wide range of research and innovation investments; from investments in basic research to R&D tax credits. We find that a wide variety of measures of the outputs and impacts of investments in research and innovation (over 30) were employed, and that most studies report a positive impact. Several studies point to the importance of investments in basic research, and provide support for theories of geographically-mediated knowledge spillovers and socially-embedded economic activity. We conclude that while the emergent state of knowledge on the design and assessment of government investments in research and innovation precludes the identification of best practices, an understanding of the literature, coupled with an understanding of contextual specifics, will enable the design of interventions and assessment methodologies that are informed by the best available evidence.

Connecting the dots in translational research

Translational research is currently one of the top priorities for the US National Institutes of Health (NIH), as recently highlighted by its Director, Francis Collins (An audience with... Francis Collins. Nature Rev. Drug Discov. 10, 14 (2011))1. The rise of this concept has been fuelled by the widely held belief that major investments in basic biomedical research will not bear fruit in terms of new medicines without new initiatives or approaches to bridge the 'valley of death' that is considered to be a key cause for the stalling of industry pipelines. Indeed, such is the power of this concept that it has recently led to structural reconfiguration of the NIH to create the National Center for Advancing Translational Sciences (NCATS), which was formally authorized by the US Congress in December 2011. The fiscal year 2012 budget for the NCATS was ~US$574 million and it is requesting ~$639 million for 2013 (Ref. 2).

Basic research, openness, and convergence

We study a model where economic growth is fueled by public basic-research investment and the importation of leading technology from foreign countries. In each period, the government chooses the amount of basic research, balancing the costs and benefits of stimulating growth through both channels. We establish the existence of steady states and the long-run share of technologically advanced sectors in the economy. Then we explore how different degrees of openness affect long-term incentives to invest in basic research. Our main insight is that higher openness tends to encourage more investment in basic research, which, in turn, yields a larger share of leading sectors. If, however, there are prospects of importing major technology advances, highly open countries will reduce basic research as such imports become particularly valuable.

BASIC RESEARCH AND DEVELOPMENT IN VERTICAL MARKETS*

This paper considers the role of basic research and development (R&D) investment in vertical markets in which an incumbent owner of a basic technological input faces potential competition. We identify the conditions under which the socially optimal investment in basic research involves entry by new firms. Our main insight is that there is a role for public investment in R&D that appears to have been overlooked in the existing literature. This role draws on the idea that basic R&D adds to the credibility of the threat of the potential development of alternative technologies by reducing their implementation costs.

An interview with Angela Nieto

Angela Nieto is Full Professor at the Instituto de Neurociencias (CSIC-UMH) in Alicante, Spain, and Head of the institute's Developmental Neurobiology Unit. She is also the current president of the Spanish Society for Developmental Biology (Sociedad Española de Biología del Desarollo, SEBD). We interviewed her to talk about the plans of the SEBD for the coming years.

The Impact of Public Basic Research on Industrial Innovation: Evidence from the Pharmaceutical Industry

While most economists believe that public scientific research fuels industry innovation and economic growth, systematic evidence supporting this relationship is surprisingly limited. In a recent study, Acemoglu and Linn (2004) identified market size as a significant driver of drug innovation in the pharmaceutical industry, but they did not find any evidence supporting science-driven innovation from publicly funded research. This paper uses new data on biomedical research investments by the U.S. National Institutes of Health (NIH) to examine the contribution of public research to pharmaceutical innovation. The empirical analysis finds that both market size and NIH funded basic research have economically and statistically significant effects on the entry of new drugs with the contribution of public basic research coming in the earliest stage of pharmaceutical drug discovery. The analysis also finds a positive return to public investment in basic biomedical research.

Promoting Innovation and Convergence in Military Medicine: Technology-Inspired Problem Solving

Large organizations develop layers and rules for members to operate within accepted processes and conventions whereas innovation tends to occur in a less constrained, less conventional, and less risk averse environment. This basic cultural difference creates a need for protected semi-autonomous centers that cultivate great ideas, providing freedom to explore new concepts and harbor the zealots to champion them past institutional barriers to change. The management objective at the Telemedicine and Advanced Technology Research Center (TATRC) is to advocate and accelerate technology development and ensure benefi cial implementation in the shortest possible time. TATRC accomplishes this objective through integrating multidisciplinary teams that combine engineering technology and physical sciences with both basic and applied clinical biosciences to solve medical problems. This convergence in medical research complements Department of Defense (DoD) investments in long term basic research and large investments in high risk problem solving. TATRC successes in this technology push to satisfy clinical need began with radiograph digitization standards and has continued to spin out medical systems and program initiatives to new DoD core programs in rehabilitative medicine (e.g., regenerative medicine, advanced prosthetics, vision research, and integrative pain management), medical modeling and simulation, and current combat zone telemedicine applications. TATRC technology scouts look for transformational approaches across traditional boundaries and provide active assistance to build new capabilities and to successfully complete projects through commercialization and DoD implementation. Many near term problems can be addressed by mature technologies in medical robotics, synthetic biology, tissue engineering, nano- and biomaterials science, medical imaging, and neuroengineering. Everyday technologies such as smartphones can be immediately harnessed for better access to medical care, improved safety and efficiency in medicine, technology management and ultimately reduced medical costs. The end result of this culture of convergence can be transformational, calling for disruptive change in technology and capability as exemplifi ed by telemedicine and m-Health, fostered through the unique TATRC research management model.

Susceptibility Genes in Hypertension

Hypertension is a complex, multifactorial disease; genetic factors represent one third to half of the inter-individual variability of blood pressure values. Among the causes of secondary hypertension are a group of disorders with a Mendelian inheritance pattern. Recent advances in molecular biology have revealed the pathogenesis of hypertension in many of these conditions. Remarkably, the mechanism in every case has proved to be upregulation of sodium Na reabsorption in the distal nephron, with accompanying expansion of extracellular volume. On the contrary in the essential hypertension the underlying pathogenetic mechanism is more complex because of interplay between several 'risk' genes and environmental factors. It is assumed that blood pressure is under the control of a large number of genes each of which has only relatively mild effects. It has therefore been difficult to discover the genes that contribute to blood pressure variation using traditional approaches including candidate gene studies and linkage studies. Recent development of genotyping technology made large scale genome-wide association studies possible. This approach and the study of monogenic forms of hypertension has led to the discovery of novel and robust candidate genes for human essential hypertension, many of which require functional analysis in experimental models. This review summarizes the current findings for candidate genes associated with blood pressure and focuses on recent advances and future potential of pharmacogenetics of hypertension, with the intent to clarify what amount of these investments in basic science research will be delivered into benefits to patients.

Bridging Taxonomic and Disciplinary Divides in Infectious Disease

Pathogens traverse disciplinary and taxonomic boundaries, yet infectious disease research occurs in many separate disciplines including plant pathology, veterinary and human medicine, and ecological and evolutionary sciences. These disciplines have different traditions, goals, and terminology, creating gaps in communication. Bridging these disciplinary and taxonomic gaps promises novel insights and important synergistic advances in control of infectious disease. An approach integrated across the plant-animal divide would advance our understanding of disease by quantifying critical processes including transmission, community interactions, pathogen evolution, and complexity at multiple spatial and temporal scales. These advances require more substantial investment in basic disease research.

The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry

While most economists believe that public scientific research fuels industry innovation and economic growth, systematic evidence supporting this relationship is surprisingly limited. In a recent study, Acemoglu and Linn (2004) identified market size as a significant driver of drug innovation in the pharmaceutical industry, but they did not find any evidence supporting science-driven innovation from publicly funded research. This paper uses new data on biomedical research investments by the U.S. National Institutes of Health (NIH) to examine the contribution of public research to pharmaceutical innovation. The empirical analysis finds that both market size and NIH funded basic research have economically and statistically significant effects on the entry of new drugs with the contribution of public basic research coming in the earliest stage of pharmaceutical drug discovery. The analysis also finds a positive return to public investment in basic biomedical research.

Globalization and strategic research investments

Abstract We develop a general equilibrium model of international trade with heterogeneous firms, where countries can invest into basic research to improve their technological potential. These research investments tighten firm selection and raise the average productivity of firms in the market, thereby implying lower consumer prices and higher welfare. In an open economy there is also a strategic investment motive, since a higher technological potential gives domestic firms a competitive advantage in trade. Countries tend to over-invest due to this strategic motive. There are thus welfare gains from coordinating research investments. The over-investment problem turns to an under-investment problem if there are sufficiently strong cross-country spillovers of basic research investments.

Globalization and Strategic Research Investments

We develop a general equilibrium model of international trade with heterogeneous firms, where countries can invest into basic research to improve their technological potential. These research investments tighten firm selection and raise the average productivity of firms in the market, thereby implying lower consumer prices and higher welfare. In an open economy, there is also a strategic investment motive since a higher technological potential gives domestic firms a competitive advantage in trade. Countries tend to over-invest due to this strategic motive. There are thus welfare gains from coordinating research investments. The over-investment problem turns to an under-investment problem if there are sufficiently strong cross-country spillovers of basic research investments.

Cancer biology and genomics: translating discoveries, transforming pathology

Advances in our understanding of cancer biology and discoveries emerging from cancer genomics are being translated into real clinical benefits for patients with cancer. The 2011 Journal of Pathology Annual Review Issue provides a snapshot of recent rapid progress on multiple fronts in the war on cancer or, more precisely, the wars on cancers. Indeed, perhaps the most notable recent shift is reflected by the sharp increase in understanding the biology of multiple specific cancers and using these new insights to inform rationally targeted therapies, with often striking successes. These recent developments, as reviewed in this issue, show how the long-term investments in basic cancer research are finally beginning to bear fruit.

Basic Research, Openness, and Convergence

We study a model where economic growth is fueled by public basic-research investment and the importation of leading technology from foreign countries. In each period, the government chooses the amount of basic research, balancing the cost and benefits of stimulating growth through both channels. We establish the existence of steady states and the long-run share of technologically advanced sectors in the economy. Then, we explore how different degrees of openness affect long-term incentives to invest in basic research. Our main insight is that higher openness tends to encourage more investment in basic research which, in turn, yields a larger share of leading sectors. If, however, there are prospects of importing large technology advancements, highly open countries will reduce basic research as such imports become particularly valuable.